Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06371157 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

StatusRecruiting
PhasePhase 3
SponsorAkeso
Started2024-08-02
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 12, 2025 (before its estimated October 25, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-03-11
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-07-02→confirmed 2024-08-02
Study sites7→4
2024-04-15
minor
Original filing
96 trials monitored
See 1 trial at risk
1,505 trials monitored
See 60 trials at risk
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
Trial Details
NCT Number NCT06371157
Lead Sponsor Akeso
Conditions Hepatocellular Carcinoma
Enrollment 469 participants
Start Date 2024-08-02
Primary Completion 2025-10-25 (estimated)
Study Completion 2026-05-23 (estimated)
Updated on ClinicalTrials.gov 2025-03-12